Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1997-04-11
1999-10-19
Wortman, Donna C.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
435 731, C12Q 168, G01N 33569
Patent
active
059687410
ABSTRACT:
The present invention provides serological and genetic methods of diagnosing a medically resistant clinical subtype of ulcerative colitis UC. The present invention provides a method of diagnosing a medically resistant clinical subtype of UC by determining the presence or absence of anti-Saccharomyces cerevisiae antibodies (ASCA) in a patient with UC, where the presence of ASCA indicates the medically resistant clinical subtype of UC. The present invention also provides a method of diagnosing a medically resistant clinical subtype of UC by determining the presence or absence of a TNFa2b1c2d4e1 haplotype in a patient with UC, where the presence of said TNFa2b1c2d4e1 haplotype indicates the medically resistant clinical subtype of UC. In addition, the invention provides a method of diagnosing a medically resistant clinical subtype of UC by determining the presence or absence of a TNFa2b1c2d4e1 haplotype in a patient with UC and determining the presence or absence of ASCA in the patient with UC, where the presence of said TNFa2b1c2d4e1 haplotype indicates the medically resistant clinical subtype of UC and the presence of ASCA independently indicates the medically resistant clinical subtype of UC. The invention further provides kits for diagnosing a medically resistant clinical subtype of UC containing antigen specific for ASCA and one or more oligonucleotide primers complementary to a nucleotide sequence flanking TNF microsatellite locus TNFa, TNFb, TNFc, TNFd or TNFe.
REFERENCES:
Barnes et al., "SErum antibodies reactive with Saccharomyces cerevisiae in inflammatory bowel disease: is IgA antibody a marker for Crohn's disease?", Int. Arch. Allergy Appl. Immunol; 92:9-15, 1990.
Colombel et al., Evidence for a specific antibody response to Saccharomyces cerevisiae oligomannosidic epitopes in Crohn's disese. Gastroenterology; 108:A800, Apr. 1995.
Colombel et al., "Anti-Saccharomyces cerevisiae antibodies: a new subclinical marker for Crohn's disease", Gastroenterology; 110:A886, May 1996.
Plevy et al.,"Tumor necrosis factor microsatelites define a Crohn's disease-associated haplotype on chromosome 6", Gastroenterology; 110:1053-1060, 1996.
Wiedbrauk et al., "Introduction to molecular methods for virus detection", Diagnostic Molecular Virology Workshop, Pan American group for Rapid Viral Diagnosis, Clearwater Beach, Florida, Apr. 1995.
Faille et al., "Evaluation of an Enzyme Immunoassay Using Neoglycolipids Constructed from Candida albicans Oligomannosides to Define the Specificity of Anti-Mannan Antibodies," Eur. J. Clin. Microbiol. Infect. Dis. 11:438-446 (1992).
Giaffer et al., "Antibodies to Saccharomyces cerevisiae in Patients With Crohn's Disease and Their Possible Pathogenic Importance," Gut 33:1071-1075 (1992).
Hanauer, "Inflammatory Bowel Disease," New Engl. J. Med. 334:841-848 (1996).
Hanauer and D'Haens, "Medical Management of Ulcerative Colitis," in Targan and Shanahan, Inflammatory Bowel Disease: From Bench to Bedside Williams and Wilkens, pp. 545-561 (1994).
Jongeneel et al., "Extensive Genetic Polymorphism in the Human Tumor Necrosis Factor Region and Relation to Extended HLA Haplotypes," Proc. Natl. Acad. Sci. USA 88:9717-9721 (1991).
Lindberg et al., "Antibody (IgG, IgA, and IgM) to Baker's Yeast (Saccharomyces cerevisiae), Yeast Mannan, Gliadin, Ovalbumin and Betalactoglobulin in Monozygotic Twins with Inflammatory Bowel Disease," Gut 33:909-913 (1992).
Main et al., "Antibody to Saccharomyces cerevisiae (baker's yeast) in Crohn's Disease," British Medical Journal 297:1105-1106 (1988).
McKenzie et al., "Antibody to Selected Strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's Disease," Gut 31:536-538 (1990).
McKenzie et al., "Antigenic Heterogeneity of Strains of Saccharomyces cerevisiae and Candida albicans Recognized by Serum Antibodies from Patients with Crohn's Disease," FEMS Microbiology Immunology 89:219-224 (1992).
Nedospasov et al., "DNA Sequence Polymorphism at the Human Tumor Necrosis Factor (TNF) Locus," J. Immunology 147:1053-1059 (1991).
Plevy et al., "Increased Mucosal TNF-.alpha. mRNA Levels and Numbers of TNF-.alpha. Producing Cells are Unique to Crohn's Disease Musosal Inflammation," Gastroenterology 106:A754 (1994).
Plevy et al., "TNF-.alpha. mRNA Levels Differentiate Mucosal Inflammation in Crohn's Disease from Ulcerative Colitis," J. Immunol. 150:10A, abstract 41 (1993).
Plevy et al., "Tumor Necrosis Factor Microsatellites Define a Crohn's Disease-Associated Haplotype on Chromosome 6," Gastroenterology 110: 1053-1060 (1996).
Pociot et al., "Association of Tumor Necrosis Factor (TNF) and Class II Major Histocompatibility Complex Alleles with the Secretion of TNF-.alpha. and TNF-.beta. by Human Mononuclear Cells: A Possible Link to Insulin-Dependent Diabetes Mellitus," Eur. J. Immunol. 23:224-231 (1993).
Sendid et al., "Specific Antibody Response to Oligomannosidic Epitopes in Crohn's Disease," Clinical and Diagnostic Laboratory Immunology 3:219-226 (1996).
Udalova et al., "Highly Informative Typing of the Human TNF Locus Using Six Adjacent Polymorphic Markers," Genomics 16:180-186 (1993).
Yang et al., "Linkage of Crohn's Disease to the HLA Region is Consistently Detected by Multiple Nonparametric Approaches," Am. J. Human Genetics 57:A233, abst. 1348 (1995).
Yang et al., "Ulcerative Colitis: A Genetically Heterogeneous Disorder Defined by Genetic (HLA Class II) and Subclinical (Antineutrophil Cytoplasmic Antibodies) Markers," J. Clin. Invest. 92:1080-1084 (1993).
Young et al., "Lymphocyte Proliferation Response to Baker's Yeast in Crohn's Disease," Digestion 55:40-43 (1994).
Plevy Scott E.
Targan Stephan R.
Brumback Brenda G.
Cedars-Sinai Medical Center
Wortman Donna C.
LandOfFree
Methods of diagnosing a medically resistant clinical subtype of does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of diagnosing a medically resistant clinical subtype of , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of diagnosing a medically resistant clinical subtype of will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2054383